Scientific work

Doç. Dr. Nuran Katgı

13 publications. The source of the information is stated next to each publication.

Back to profile

  1. Toplumdan Kökenli Pnömoni Nedeniyle Hastanede Yatan Yaşlı Hastaların (> 65 Yaş) Özellikleri ve Ekonomik Yükü – Abant Medical Journal, 2022; Katgı N., Çimen P., Ayrancı A., Tuksavul F.F.

    Source: medicana.com.tr profile page

  2. Telisotuzumab Vedotin Monotherapy in Previously Treated c-MET–Overexpressing Non-Squamous EGFR Wild-Type Advanced NSCLC: LUMINOSITY Trial – Updated Analysis – Journal of Thoracic Oncology, 2025; Katgı N. ve ark.

    Source: medicana.com.tr profile page

  3. Telisotuzumab Vedotin Monotherapy in NSCLC: Primary Analysis of LUMINOSITY Trial – Journal of Clinical Oncology, 2024; Katgı N. ve ark.

    Source: medicana.com.tr profile page

  4. Efficiency and Reliability of Bronchoscopic Lung Volume Reduction Coil Application in Severe Emphysema – 2024; Katgı N. ve ark.

    Source: medicana.com.tr profile page

  5. Comparison of Alectinib and Crizotinib in ALK Positive Advanced NSCLC: Real-Life Data – Thoracic Research and Practice, 2023; Katgı N. ve ark.

    Source: medicana.com.tr profile page

  6. Relationship Between Thyroid Transcription Factor 1 (TTF 1) Positivity and EGFR Mutation in Lung Adenocarcinoma – Eurasian Journal of Pulmonology, 2023; Katgı N. ve ark.

    Source: medicana.com.tr profile page

  7. COVID-19 Hastalarında Prognostik Faktörler ve Eozinofillerin Rolü – Journal of İzmir Chest Hospital, 2023; Katgı N. ve ark.

    Source: medicana.com.tr profile page

  8. Prediction of EGFR and ALK Mutations by 18F FDG PET/CT Texture Analysis in Lung Adenocarcinoma – Nüklearmedizin, 2022; Katgı N. ve ark.

    Source: medicana.com.tr profile page

  9. Prognostic Value of 18F FDG PET/CT Metabolic Parameters in Advanced Lung Adenocarcinoma – Molecular Imaging and Radionuclide Therapy, 2022; Katgı N. ve ark.

    Source: medicana.com.tr profile page

  10. Real-Life Comparison of Afatinib vs Erlotinib in Rare EGFR Exon 18/20 Mutations: TOG Study – Journal of Cancer Research and Clinical Oncology, 2022; Katgı N. ve ark.

    Source: medicana.com.tr profile page

  11. Complication and Cost Analysis of Transbronchial Lung Cryobiopsy and Awake VATS in Interstitial Lung Disease Diagnosis – Sarcoidosis, Vasculitis and Diffuse Lung Diseases, 2022; Katgı N. ve ark.

    Source: medicana.com.tr profile page

  12. Diagnostic Efficacy of EBUS TBNA in Benign Diseases in High Tuberculosis Prevalence Regions – 2020; Katgı N. ve ark.

    Source: medicana.com.tr profile page

  13. Comparison of TBLC and Conventional Transbronchial Biopsy in the Diagnosis of Parenchymal Lung Diseases – 2019; Katgı N. ve ark.

    Source: medicana.com.tr profile page